Recida Therapeutics Inc, a biopharmaceutical company focused on developing treatments for serious antibiotic-resistant infections, has raised $8.5 million in Series A funding. Frazier Healthcare Partners led the round.
Source: Press Release
Recida Therapeutics Inc, a biopharmaceutical company focused on developing treatments for serious antibiotic-resistant infections, has raised $8.5 million in Series A funding. Frazier Healthcare Partners led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: